ATE511849T1 - Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle - Google Patents

Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle

Info

Publication number
ATE511849T1
ATE511849T1 AT97914975T AT97914975T ATE511849T1 AT E511849 T1 ATE511849 T1 AT E511849T1 AT 97914975 T AT97914975 T AT 97914975T AT 97914975 T AT97914975 T AT 97914975T AT E511849 T1 ATE511849 T1 AT E511849T1
Authority
AT
Austria
Prior art keywords
peptides
hla
molecules
binding affinity
increased binding
Prior art date
Application number
AT97914975T
Other languages
German (de)
English (en)
Inventor
Alessandro Sette
Robert Chesnut
John Sidney
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Application granted granted Critical
Publication of ATE511849T1 publication Critical patent/ATE511849T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97914975T 1996-03-11 1997-03-10 Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle ATE511849T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1311396P 1996-03-11 1996-03-11
PCT/US1997/003778 WO1997033602A1 (en) 1996-03-11 1997-03-10 Peptides with increased binding affinity for hla molecules

Publications (1)

Publication Number Publication Date
ATE511849T1 true ATE511849T1 (de) 2011-06-15

Family

ID=21758378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97914975T ATE511849T1 (de) 1996-03-11 1997-03-10 Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle

Country Status (9)

Country Link
EP (1) EP0914142B9 (https=)
JP (2) JP2001504799A (https=)
CN (1) CN1225590A (https=)
AT (1) ATE511849T1 (https=)
AU (1) AU2203797A (https=)
BR (1) BR9708161A (https=)
CA (1) CA2248657A1 (https=)
ES (1) ES2367640T3 (https=)
WO (1) WO1997033602A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
EP1064022A4 (en) * 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PROTEINS AND THEIR USE
WO2000044775A2 (en) * 1999-01-27 2000-08-03 Epimmune Inc. Identification of broadly reactive hla restricted t cell epitopes
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
AU1661201A (en) * 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP2075582A3 (en) 2000-07-12 2010-01-06 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
AU2002246708A1 (en) 2000-12-15 2002-08-12 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IL158860A0 (en) * 2001-05-15 2004-05-12 Agensys Inc Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer and pharmaceutical compositions containing the same
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
AU2002322009A1 (en) 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
EP1495322A4 (en) * 2002-04-05 2006-09-06 Epimmune Inc HETEROKLITIC ANALOGUES AND ASSOCIATED METHODS
WO2004000873A2 (en) * 2002-06-25 2003-12-31 City Of Hope Adjuvant-free peptide vaccine
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
JP2006508163A (ja) 2002-11-27 2006-03-09 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
CA2515699C (en) 2003-02-10 2015-01-27 Aya Jakobovits Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
RU2005141341A (ru) 2003-05-30 2006-06-10 Эйдженсис, Инк., Сша (Us) Полинуклеотид, родственный антигену стволовых клеток простаты (psca), и кодируемый им белок (пептид), гибридома и трансгенное животное для продуцирования антител, композиция для лечения, профилактики, диагностики и прогноза течения раковых заболеваний на их основе (варианты), способ определения их присутствия в исследуемом образце, способ генерации иммунного ответа, способ доставки цитотоксического или диагностического агента в клетку, способ ингибирования роста раковых клеток с их использованием
AU2005250370B2 (en) 2004-05-28 2010-04-01 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
CA2603093A1 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
WO2007083807A1 (ja) * 2006-01-23 2007-07-26 Green Peptide Co., Ltd. Ｃ型肝炎ウイルス由来ペプチド
JP5067624B2 (ja) 2006-02-07 2012-11-07 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
JPWO2008044567A1 (ja) 2006-10-12 2010-02-12 日本電気株式会社 Ｈｌａ結合性ペプチド、その前駆体、それをコードするｄｎａ断片および組み換えベクター
JP2011502484A (ja) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
EP2391635B1 (en) * 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CN103906531A (zh) 2011-05-26 2014-07-02 金纽斯生物科技投资有限责任公司 调节的免疫优势疗法
MA47678A (fr) 2017-03-03 2021-05-26 Treos Bio Ltd Plateforme personnalisée d'identification de peptide immunogène
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US20050271676A1 (en) * 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
DK0726758T3 (da) * 1993-08-02 2003-03-03 Scripps Research Inst Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus
CA2173138A1 (en) * 1993-10-19 1995-04-27 Masafumi Takiguchi Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide

Also Published As

Publication number Publication date
EP0914142B9 (en) 2012-01-04
ES2367640T3 (es) 2011-11-07
CA2248657A1 (en) 1997-09-18
EP0914142A4 (en) 2004-06-23
EP0914142A1 (en) 1999-05-12
BR9708161A (pt) 1999-07-27
EP0914142B1 (en) 2011-06-08
AU2203797A (en) 1997-10-01
JP2009108097A (ja) 2009-05-21
WO1997033602A1 (en) 1997-09-18
CN1225590A (zh) 1999-08-11
JP2001504799A (ja) 2001-04-10

Similar Documents

Publication Publication Date Title
ATE511849T1 (de) Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
NL194533B (nl) Biopsienaaldsamenstel.
DE69017300D1 (de) Nager mit geringem Verschleiss für chirurgischen Retraktor.
DE69711083D1 (de) Kontaktstift für prüfzwecke
AU2002366641A1 (en) Methods for inhibiting ocular processes
DE69634272D1 (de) Ventil für medizinische Anwendungen
DE3850726D1 (de) Ventil für medizinisches Instrument.
DE59005283D1 (de) Adaptierbarer schaft für eine endoprothese.
CA2169381A1 (en) Enhanced cross-linking of natural tissues
DE19780486T1 (de) Druck-Zug-Ventilanordnung für einen Motorzylinder
WO1999057144A3 (en) Human transcriptional regulator molecules
BR9804676A (pt) Processo para o teste de um dispositivo de embreagem automatizado.
BR9607854A (pt) Processos para a medição da taxa de degradação de uma proteína do corpo e para obtenção de informação referente à degradação de proteína em um paciente utilização de um isômero sintético de um peptídeo e de um anticorpo anticorpo capa de células análogo de peptídeo sintético e kit de análise para utilização em um processo de análise
DE69721506D1 (de) Betriebsverfahren für eine ionenfalle
DE69625833D1 (de) Testkarte für Analysen
DE59009116D1 (de) Versuchsträger.
DE60013093D1 (de) Methoden und kits zum sequenzieren von polypeptiden
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
DE59003598D1 (de) Ausrüstungsteil für Fahrzeuge.
DE59610901D1 (de) Gehäuse für eine elektrische Baugruppe
ATE86651T1 (de) Nichtalkalisches suessen von kohlenwasserstofffraktionen.
DE69023357D1 (de) Fluoreszenz-Polarisationsimmunoassay für Methadon.
NO900052D0 (no) Fremgangsmaate for betjening av en oljebroenn til havs.
PE20399A1 (es) Muteina ob
DE69530410D1 (de) Methoden zur identifizierung von individuen, die an einer zellulären abnormalität leiden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties